Clinical Trials Logo

Filter by:
NCT ID: NCT04228133 Completed - PTSD Clinical Trials

Home-Delivered Attention Control Treatment for Post Traumatic Stress Disorder (PTSD)

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The aim of the study is to explore the efficacy of home-delivered Attention Control Training (ACT) for Posttraumatic Stress Disorder (PTSD). Three randomized controlled trials have shown that attention bias modification protocols applying attention control training (ACT) aimed to balance attention between threat-related and neutral stimuli are efficient in reducing PTSD symptoms. However, contrary to in-clinic administration, such as applied in the above mentioned studies, home-delivered attention bias modification was not effective in reducing symptoms among treatment-seeking patients. It is crucial to continue examining the efficacy of home-delivered ACT as PTSD entails functional impairments that might impede treatment-seeking patients from reaching to clinics to receive treatment. This could also inform other ABM protocols designated to treat other disorders.

NCT ID: NCT04220866 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). The primary study hypotheses are that IT ulevostinag in combination with pembrolizumab results in a superior Objective Response Rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), compared to pembrolizumab alone: 1. In participants with a tumor that has a programmed cell death-ligand 1 (PD-L1) Combined Positive Scoring (CPS) ≥ 1, and 2. In participants with a tumor that has a PD-L1 CPS ≥ 20.

NCT ID: NCT04220359 Completed - Clinical trials for Hemodynamic Instability

Early Identification of Clinical Deterioration Using a Wearable Monitoring Device

Start date: July 6, 2020
Phase:
Study type: Observational

This study aims to provide myriad of physiological parameters in patients admitted in an internal medicine department, and which are defined as being in an increased risk of clinical deterioration within the first 72-hours after admission. The investigators will also conduct a retrospective comparison between physiological changes in patients who did deteriorate to those who did not. This will form the basis for the development of an algorithm for early prediction and warning of physiological and clinical deterioration during the first 72-hours of admission.

NCT ID: NCT04220320 Completed - Clinical trials for Induction of Labor Affected Fetus / Newborn

The Success of Labor Induction Based on a Modified BISHOP Score.

Start date: March 1, 2020
Phase:
Study type: Observational

Pregnant women at term will be divided randomly into 3 groups: 1. Gynecological evaluation based on classic BISHOP score. 2. Gynecological evaluation based on a modified BISHOP score. 3. Gynecological evaluation based on cervical length as measured by transvaginal sonography. After gynecological evaluation, women will undergo induction of labor based on obstetric evaluation according to the group they were part of.

NCT ID: NCT04220294 Completed - Clinical trials for Suture Line Infection

Subcutaneous Continuous Versus Interrupted Sutures During Cesarean Section.

Start date: January 10, 2020
Phase: N/A
Study type: Interventional

A comparison of the rate of surgical site infections after cesarean section depending on the type of suture used for subcutaneous closure-continuous versus interrupted.

NCT ID: NCT04218851 Completed - Clinical trials for Invasive Aspergillosis

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Start date: July 2, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).

NCT ID: NCT04217811 Completed - Neutropenia Clinical Trials

Late Neutropenia in VLBW Preterm Babies

Start date: January 1, 2020
Phase:
Study type: Observational

There are rare reports regarding late neutropenua in very low birth weight preterm infants. The investigators wish to characterize it among our population, and assess its consequenses and the postnatal menagement of the infants.

NCT ID: NCT04215627 Completed - Critically Ill Clinical Trials

Comparing the PiCCO Monitor to the Non-invasive Biobeat (BB)-316PW in ICU Patients

Start date: December 26, 2019
Phase:
Study type: Observational

The aim of this study is to compare hemodynamic monitoring using the invasive PiCCO device to the BB-613PW wireless, non-invasive PPG-based device, in critically ill patients within the ICU, suffering from hemodynamic instability and in need of vasopressor support. Data will be gathered prospectively and analysed retrospectively.

NCT ID: NCT04214106 Completed - Delirium Clinical Trials

Thiamine Administration and Prevalence of Delirium in the Intensive Care Unit: A Before-after Study

Start date: February 19, 2020
Phase:
Study type: Observational

Delirium is a very common condition among ICU-admitted patients, and its prevalence is estimated between 30-40%. Delirium is associated with increased morbidity and mortality and future cognitive decline, along with increased ventilation-dependency and other complications. There are multiple risk factors for delirium, including deficiencies of micronutrients. Thiamine deficiency is associated with specific neurological syndromes, including Wernicke and Korsakoff syndromes and Delirium Tremens. Several studies demonstrated significant thiamine deficiency among ICU-admitted patients (prevalence of 30-70%) without known risk factors, such as alcohol dependency. Thiamine deficiency may cause delirium in those patients. Intravenous thiamine had been safely used for decades, for several indications. Lately, thiamine has been advocated for therapy in patients with septic shock, and its use in intensive care units has increased worldwide. Since 2016, thiamine has been routinely administered in our intensive care unit. Considering the theoretical association between thiamine deficiency and ICU-related delirium, the investigators aim to investigate whether the routine use of thiamine has been associated with decreased prevalence of delirium among ICU patients when compared to the pre-routine thiamine administration era.

NCT ID: NCT04213859 Completed - Fear of Flying Clinical Trials

Emotional Processes in VR Exposure Treatment for Flight Phobia

Start date: December 24, 2019
Phase: N/A
Study type: Interventional

This study will assess emotional processes and their relation to treatment outcomes during Virtual reality exposure therapy for Flight Phobia. The researchers hypothesize treatment outcomes will be associated with positive changes in emotional constructs